Horizon Blue Cross Blue Shield of New Jersey
08/17/2026 | Press release | Archived content
Medical Injectables Program Update: September 2026
We are making the following changes to our Medical Injectables Program (MIP) as part of our commitment to helping ensure that the medications provided to our members are medically necessary and cost effective.
INJECTABLE MEDICATIONS SUBJECT TO MEDICAL NECESSITY AND APPROPRIATENESS REVIEW (MNAR)
New Codes/Drugs Subject to MNAR
For services rendered on and after September 24th, 2026, Prime Therapeutics Management will conduct MNAR for the following injectable medications as part of the MIP.
| BRAND NAME | GENERIC NAME | HCPCS | NATIONAL DRUG CODE |
| Sarclisa Escena | isatuximab-irfc | J9999 | 0024-0674-01 |
Published on: August 17, 2026, 02:26 a.m. ET
Last updated on: August 17, 2026, 02:27 a.m. ET
Horizon Blue Cross Blue Shield of New Jersey published this content on August 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 25, 2026 at 08:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]